Scientific committee

Cotne Javakhishvili

Scientific Supervisor

Tsotne Javakhishvili began his scientific career at the Tbilisi Institute of Plant Biochemistry after graduating from the Biology Department of Tbilisi State University. Furthermore, he completed his postgraduate studies at the Biology Center and the Institute of Molecular Genetics of the Union Academy.

In later years, Tsotne Javakhishvili was invited to the United States, first as a professor in the Department of Molecular Genetics at Evergreen State College in Olympia, Washington, and then in the Department of Experimental Medicine at the Scripps Research Institute, to participate in research on genomic programs of cellular development and differentiation.

Since the mid-1990s, Tsotne Javakhishvili has worked in the Molecular Biology Department of Diversa Biotechnology Company in his capacity as the head of Complex Molecular Cloning, a.k.a. directed evolution and research. From 2003-2013, he was scientific founder and director of the Molecular Technology Division of AmbRX Biotechnology Company along with Peter Schultz and Richard DeMarkis. During his tenure in these positions, Tsotne Javakhishvili has been involved in research on so-called “next generation” genetic code expansion and genomic engineering. He worked in the area of molecular principles of synthetic oncotherapeutics design.

From 2014-2019, Tsotne Javakhishvili worked at DuPont Corporation, first as a senior manager of Genomic Engineering and Technology Research and then as a director. In recent years, he has worked at the California Institute for Biomedical Research and the Scripps Institute, as well as at several international biotechnology companies as the head and consultant of genomic reprogramming and synthetic biology programs. Since 2020, he has been a scientific supervisor of Genomics.

Tsotne Javakhishvili’s research areas and scientific and technical interests include genetic code expansion, genome editing, synthetic life and evolution, genetically modified organisms, and next-generation immunotherapeutic design. He is the author of a number of scientific and technical publications and patents.